Clonal human (hNT) neuron grafts for stroke therapy: Neuropathology in a patient 27 months after implantation

Peter T. Nelson, Douglas Kondziolka, Lawrence Wechsler, Steven Goldstein, James Gebel, Sharon DeCesare, Elaine M. Elder, Paul J. Zhang, Alan Jacobs, Michael McGrogan, Virginia M.Y. Lee, John Q. Trojanowski

Research output: Contribution to journalArticlepeer-review

228 Scopus citations


Although grafted cells may be promising therapy for stroke, survival of implanted neural cells in the brains of stroke patients has never been documented. Human NT2N (hNT) neurons derived from the NTera2 (NT2) teratocarcinoma cell line were shown to remain postmitotic, retain a neuronal phenotype, survive > 1 year in host rodent brains and ameliorate motor and cognitive impairments in animal models of ischemic stroke. Here we report the first postmortem brain findings of a phase I clinical stroke trial patient implanted with human hNT neurons adjacent to a lacunar infarct 27 months after surgery. Neuro-filament immunoreactive neurons were identified in the graft site, fluorescent in situ hybridization revealed polyploidy in groups of cells at this site just like polyploid hNT neurons in vitro, and there was no evidence of a neoplasm. These findings indicate that implanted hNT neurons survive for > 2 years in the human brain without deleterious effects.

Original languageEnglish
Pages (from-to)1201-1206
Number of pages6
JournalAmerican Journal of Pathology
Issue number4
StatePublished - 2002

Bibliographical note

Funding Information:
Supported by Layton Bioscience, Inc.

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Clonal human (hNT) neuron grafts for stroke therapy: Neuropathology in a patient 27 months after implantation'. Together they form a unique fingerprint.

Cite this